ClinicalTrials.gg
Not yet recruitingNCT05181189Updated Oct 22, 2026

NMDA Enhancement Combined With Omega-3 for Early Dementia

A Phase 2 interventional study of DAOIB+Omega-3 and DAOIB+Placebo in Omega 3 Fatty Acids and Dementia, sponsored by Chang Gung Memorial Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know

Updated Oct 22, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
50 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Dementia by Chang Gung Memorial Hospital — 9 open to participants now, 10 under way, none of them phase 3. Dementia · Chang Gung Memorial Hospital.

Planned enrollment
5th of 21
140 · median 97
Started
2027
with 1 other
Phase 2
7 of 23
2 open now
Registered
14th of 23
by date

Among the 23 studies in Dementia by Chang Gung Memorial Hospital, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2027, is one of 7 in phase 2, and was the 14th registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

9 of the 23 studies in Dementia by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 50 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Dementia by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: [1] DAOIB + omega-3; [2] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.

03

Conditions studied

  • Omega 3 Fatty Acids
  • Dementia

Browse trials for

04

Who can participate

Ages eligible
50 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
  • between 10-26
  • CDR 1 or 0.5

Exclusion criteria

Exclusion Criteria:

  • Hachinski Ischemic Score > 4
  • Substance abuse/dependence
  • Parkinson disease, epilepsy, dementia with psychotic features
  • Major depressive disorder
  • Major physical illnesses
  • memantine or special omega-3 fatty acids therapy within 3 months before enrollment
  • Severe visual or hearing impairment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    DAOIB+Omega-3

    Drug: DAOIB+Omega-3

  • Placebo comparator
    DAOIB+Placebo

    Drug: DAOIB+Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

    Alzheimer's disease assessment scale-cognitive subscale scores range from 0 (best) to 70 (worst)

    Time frame: week 0, 8, 16, 24

Secondary outcomes

  1. Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

    Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24

    Time frame: week 8, 16, 24

  2. Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24

    Change from baseline in Mini-Mental Status examination score at week 8, 16 and 24

    Time frame: week 0, 8, 16, 24

  3. Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at week 8, 16 and 24

    Change from baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at week 8, 16 and 24

    Time frame: week 0, 8, 16, 24

  4. Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24

    The assessment appears to be a suitable instrument for evaluating activities of daily living in early-phase dementia. Its scores range from 0 (worst) to 78 (best)

    Time frame: week 0, 8, 16, 24

  5. Change from baseline in Quality of life score at week 8, 16 and 24

    Quality of life will be assessed by Medical Outcomes Study Short-Form-36 (SF-36). The SF-36 consists of eight sections: (1) vitality, (2) physical functioning, (3) bodily pain, (4) general health perceptions, (5) physical role functioning, (6) emotional role functioning, (7) social role functioning, and (8) mental health.

    Time frame: week 0, 8, 16, 24

  6. Change from baseline in the composite score of a battery of additional cognitive tests at week 24

    The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (Wechsler Memory Scale, Spatial Span), verbal/nonverbal learning and memory tests (Wechsler Memory Scale, Word Listing).

    Time frame: week 0, 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 43 non-industry phase 2 interventional studies under Dementia, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 78. This study's planned 35 months is below that.

Counting every sponsor, half of 84 studies reached it within 38 months; a quarter within 23 and three quarters within 61.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Aug 2026 → Jan 2027, primary completion Mar 2028 → Dec 2029 and completion Mar 2028 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Jan 6, 2022
StartEst.
Jan 2027was Aug 2026
Primary completionEst.
Dec 2029was Mar 2028
CompletionEst.
Dec 2029was Mar 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Jan 2027
Oct 22, 2026
Primary completion
Mar 2028→Dec 2029
Oct 22, 2026
Study completion
Mar 2028→Dec 2029
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Aug 2026→Jan 2027
    Primary completion Mar 2028→Dec 2029
    Study completion Mar 2028→Dec 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05181189
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Jan 2027 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion